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ES-62, an immunomodulator secreted by filarial nematodes, exhibits therapeutic potential in mouse models of allergic
inflammation, at least in part by inducing the desensitisation of Fc𝜀RI-mediated mast cell responses. However, in addition to
their pathogenic roles in allergic and autoimmune diseases, mast cells are important in fighting infection, wound healing, and
resolving inflammation, reflecting that mast cells exhibit a phenotypic and functional plasticity. We have therefore characterised
the differential functional responses to antigen (via Fc𝜀RI) and LPS and theirmodulation by ES-62 of themature peritoneal-derived
mast cells (PDMC; serosal) and those of the connective tissue-like mast cells (CTMC) and the mucosal-like mast cells derived from
bone marrow progenitors (BMMC) as a first step to produce disease tissue-targeted therapeutics based on ES-62 action. All three
mast cell populations were rendered hyporesponsive by ES-62 and whilst the mechanisms underlying such desensitisation have not
been fully delineated, they reflect a downregulation of calcium and PKC𝛼 signalling. ES-62 also downregulated MyD88 and PKC𝛿
in mucosal-type BMMC but not PDMC, the additional signals targeted in mucosal-type BMMC likely reflecting that these cells
respond to antigen and LPS by degranulation and cytokine secretion whereas PDMC predominantly respond in a degranulation-
based manner.
1. Introduction
Mast cells are increasingly recognised as playing an important
pathogenic role in a variety of allergic and autoimmune
diseases [1–4]. However, there is also developing evidence
of their participation in tissue repair and resolution of
inflammation [5–7], as well as for their exhibiting pathogenic
and protective roles in cancer [8, 9]. Such contradictory
evidence relating to mast cell function most likely reflects
that mast cells, which are haematopoietic cells found in
all vascularised organs [10–13], constitute a heterogeneous
cell population [14] varying in morphology, function, and
location with subpopulations being characterised by their
differential protease, eicosanoid, and proteoglycan content
[10, 13–17]. Such heterogeneity arises because bone marrow-
derived mast cell progenitors [18, 19] arrive in tissue before
they are fully matured [20] allowing the different cytokines,
hormones, and reactive oxygen and/or nitrogen species
produced by various microenvironments to essentially create
“custom-made” site-specific mast cells [12–14].
Moreover, the functional response of mast cells depends
on the stimuli received [12]; for example, following classical
activation via the IgE receptor, Fc𝜀R1, mast cells degranulate
rapidly (within minutes) to exocytose prostaglandins and
leukotrienes as well as preformed cytokines, tryptase, his-
tamine, heparin, and platelet activating factor (PAF) whilst
de novo synthesised cytokines exhibit a more delayed (hours)
release [8, 21]. However, mast cells can also be activated
independently of Fc𝜀RI and this can be initiated by cytokines
or other proinflammatory mediators [21] reflecting a direct
interaction with triggering factors such as LPS, parasite
molecules, or allergic stimuli in the skin or the mucosa.
Hence, mast cells are frequently the first cell type to respond
during inflammation [6], as evidenced by the important roles
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played by mast cells in bacterial and parasitic infections
[22–25]. However, mast cells are also able to influence
disease progress subsequently; both directly via the release
of proinflammatorymediators, and indirectly via their effects
on other immune cells, including dendritic cells (DC), T and
B cells, and macrophages [6].
Isolation of in vivo differentiated mast cell subsets is
difficult due to their limited numbers in tissue [5, 26] and
this has led to the development of in vitro culture protocols
to generate human and mouse mast cells, as defined by
their expression of CD117, Fc𝜀R1 and the IL-1 receptor family
member, ST2 (suppression of tumorigenicity 2), that can be
subclassified as distinct phenotypes due to their differential
granular phenotypic and functional responses [14]. Thus,
although mast cells make up <5% of the peritoneal cell
population, they can be expanded by in vitro culture with SCF
to create large numbers of homogenous peritoneal-derived
mast cells (PDMC) that are serosal-type mast cells and
retainmost of themorphological, phenotypic, and functional
features of mature mast cells [5, 14]. Such PDMC exhibit
differential functional responses (generating less lipid medi-
ators, chemokines, and cytokines but displaying stronger
degranulation responses) [5, 14] to bone marrow-derived
mast cells (BMMC), generated by culture in the presence of
IL-3 and SCF [27–29] and often used to represent mucosal-
type mast cells (mucosal-type BMMC) [10, 14]. Phenotyp-
ically, these BMMC, more closely resemble immature cells
and have no identifiable physiological equivalent in tissues
[5, 12]. Nevertheless, such BMMC can repopulate both the
mucosal and serosalmast cell compartmentswhen adoptively
transferred to mast cell-deficient mice, consistent with the
proposal that these cells represent precursor cells that require
additional site-specific signals to develop into mature tissue
mast cells [12, 14]. By contrast, coculture of BMMC with
fibroblasts [30, 31] generates connective tissue mast cells
(CTMC) which have been used to represent serosal mast
cells [10, 14]; more recently it has been shown that these
can be differentiated from bone marrow precursors using
SCF and IL-4 [14, 32] and CTMC have been implicated
as being involved in both autoimmunity [33] and contact
hypersensitivity [34].
The phosphorylcholine (PC)-containing excretory-
secretory filarial nematode product, ES-62 exhibits broad
anti-inflammatory properties including the desensitisation of
Fc𝜀RI-mediated mast cell responses and displays therapeutic
potential in associated mucosal allergic inflammatory
disorders such as asthma [35, 36]. As ES-62 is also protective
in autoimmune and allergic connective tissue inflammatory
pathologies such as arthritis and contact hypersensitivity,
respectively [35, 36], we have therefore investigated its effects
onmature PDMC and also on both CTMC andmucosal-type
BMMC function in order to better understand mast cell
biology as a first step to producing disease tissue-targeted
therapeutics based on ES-62 action.
2. Materials and Methods
2.1. Mice and Reagents. BALB/c and C57BL/6mice were pur-
chased from Harlan Olac and maintained at the Universities
of Glasgow and Strathclyde. All procedures were conducted
in accordance with Home Office, U.K. animal guidelines and
with the approval of the local ethical committees. Unless
otherwise stated, all reagents were obtained from Sigma.
2.2. Peritoneal Derived Mast Cells (PDMC). PDMC were
expanded as described previously [5]. Briefly, cells were
harvested following washing of the peritoneal cavity of 6–
8 week-old mice with 5mL sterile, cold RPMI 1640 by cen-
trifugation at 400 g for 5min and then resuspended in fresh
complete RPMI (RPMI with 10% FBS, 4mM L-glutamine,
100U/mL penicillin, 100𝜇g/mL streptomycin, 1mM sodium
pyruvate, 100 𝜇M nonessential amino acids, and 50𝜇M 𝛽-
mercaptoethanol; Invitrogen Life Technologies) before being
incubated at 5 × 106 cell/mL for 2 h at 37∘C in tissue culture-
treated petri dishes (Corning) to remove adherent cells.
The suspension cells were cultured at 0.3 × 106/mL in
complete RPMI supplemented with 10 ng/mL recombinant
SCF (Pepro Tech) or 4% conditioned medium from the SCF-
secreting cell line KLS-C. KLS-C is a CHO (Chinese Hamster
Ovary) cell line that produces SCF and was a kind gift
from Dr Xiaoping Zhong, Duke University Medical Center.
KLS-C cells were cultured at 37∘C in Minimum Essential
Medium alpha (MEM𝛼) without nucleosides (Invitrogen
Life Technologies) and with 10% FBS, 100U/mL penicillin,
100 𝜇g/mL streptomycin and 2.5𝜇M methotrexate. SCF-
enriched supernatant was filtered to remove cell debris and
the concentration determined by ELISA and then adjusted
with PBS to 550 ng/mL to be used at a final concentration of
22 ng/mL for PDMC.
2.3. Bone Marrow-Derived Mast Cells. Intact femurs and
tibias were dissected from BALB/c or C57BL/6 mice and sin-
gle cell suspensions were obtained by passing bone marrow
cells through a 100𝜇M nylon monofilament gauze (Cadisch
Precision Meshes) and lysis of red blood cells for 1min at
22∘C, followed by washing in PBS at 400 g.
Mucosal-type BMMC were derived by culture of bone
marrow progenitors [27–29] at 0.5 × 106/mL in RPMI with
10% FBS, 2mML-glutamine, 100U/mL penicillin, 100 𝜇g/mL
streptomycin, 1mM sodium pyruvate, 10mM HEPES, and
50𝜇M 𝛽-mercaptoethanol supplemented with conditioned
medium from KLS-C (1%; SCF) and TOP3 (3%; IL-3) cell
lines. TOP3 is a cell line that produces IL-3 and was a kind
gift fromDrMassimoGadina, NIH. TOP3 cells were cultured
at 37∘C in RPMI with 5% FBS, 2mM L-glutamine, 100U/mL
penicillin, 100 𝜇g/mL streptomycin, 1mM sodium pyruvate,
and 50 𝜇M 𝛽-mercaptoethanol and 0.4mg/mL G418. IL-
3-enriched supernatant was filtered to remove cell debris
and the concentration determined by ELISA, with the stock
concentration adjustedwith PBS to 1300 ng/mL to be used at a
final concentration of 39 ng/mL. Alternatively, mucosal-type
BMMC were derived using 10 ng/mL recombinant SCF and
10 ng/mL recombinant IL-3 (Pepro Tech).
CTMC were derived by culture of bone marrow progen-
itors [14, 32] at 0.8 × 106/mL in RPMI with 10% FBS, 4mM
L-glutamine, 100U/mL penicillin, 100𝜇g/mL streptomycin,
1mM sodium pyruvate, 100 𝜇M nonessential amino acids
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and 50 𝜇M 𝛽-mercaptoethanol supplemented with 1% KLS-
C conditioned medium (or 10 ng/mL recombinant SCF) and
1 ng/mL recombinant murine IL-4 (Pepro Tech).
PDMC, mucosal-type BMMC, and CTMC were cultured
at 37∘C/5% CO
2
in tissue culture-treated flasks (Greiner Bio-
one) for at least 28 days, with adherent cells being discarded.
A purity of >95% mast cells was routinely obtained as
evidenced by the surface expression of CD117, Fc𝜀R1 and ST2
and viability was determined by Trypan Blue staining.
2.4. Mast Cell Stimulation. Unless otherwise stated, mast
cells were sensitised with 0.5𝜇g/mL murine anti-DNP IgE
for 18 h prior to stimulation. In experiments investigat-
ing immunomodulation by ES-62, mast cells were incu-
bated with ES-62 (2𝜇g/mL) simultaneously with IgE during
the sensitisation period. Cells were then stimulated (1 ×
106 cells/mL except where indicated) by addition of medium,
0.5 𝜇g/mL DNP-HSA to cross-link Fc𝜀R1, 0.5 𝜇g/mL LPS
(Salmonella minnesota) or PMA (phorbol myristate acetate;
1 𝜇M) plus ionomycin (1 𝜇M). Reactions were terminated
after the desired culture period by centrifugation at 400 g and
supernatants aspirated for determination of mediator release
whilst the cell pellets were stored at −20∘C until subjected to
Western Blot analysis.
2.5. Preparation of Endotoxin-Free ES-62. ES-62 was puri-
fied to homogeneity from spent culture medium of adult
Acanthocheilonema viteae using endotoxin-free reagents as
described previously [37]. The purity and identity of each
batch were confirmed by SDS-PAGE and the level of endo-
toxin in the ES-62 sample was determined using a Limulus
Amebocyte Lysate (LAL) QCL-1000 kit (Lonza Biologics).
ES-62 is used at a working concentration that has an endo-
toxin reading of <0.003 endotoxin units/mL [37].
2.6. Mast Cell Phenotyping. To identify mast cells by positive
staining of heparin with Toluidine Blue, cells (0.01 × 106) were
cytofuged using a Shandon Cytospin3 (Thermo Shandon) at
500 rpm for 5min. Slides were air dried before staining with
0.5% Toluidine Blue in 0.5MHCl for 10–15min. Images were
obtained using an Olympus BX41TF microscope.
Mast cells were also phenotyped by flow cytomet-
ric analysis of lineage markers. Briefly, cells were pre-
incubated with 50𝜇L Fc receptor (FcR) blocking buffer
(anti-CD16/32, clone 2.4G2, hybridoma supernatant, 10%
mouse serum, and 0.1% sodium azide) for 20min at 4∘C
prior to incubation with the appropriate flurochrome-
conjugated or biotinylated antibodies (2 𝜇g/mL; suspended
in 50𝜇L Fc Block; CD117, eBioscience; Fc𝜀RI, eBioscience;
ST2, MD Bioproducts; and TLR4/MD2, eBioscience) for
30min, 4∘C. Following washing, for biotinylated primary
antibodies, flurochrome-conjugated streptavidin was added
for a further 30min at 4∘C. After labelling, cells were
washed twice with 3mL FACS buffer (PBS containing 2%
FBS and 2mM EDTA) at 1500 rpm for 6min, 4∘C and
then resuspended in FACS buffer. To enable exclusion of
dead cells from the analyses, cells were either stained
with Live/Dead Viability/Cytotoxicity Kit (Invitrogen) before
commencement of staining or by the addition of 1 𝜇L 7-
AAD (7-Amino Actinomycin D; eBioscience) immediately
prior to data acquisition. Cellular fluorescence data were
acquired using a Becton Dickinson LSR II or FACSCalibur
flow cytometer and analysed using FlowJo software (Tree
Star Inc). Analysis was performed on a minimum of 10,000
events.
2.7. Calcium Mobilisation. Cells were loaded with the fluo-
rescent calcium-sensing dye Fura-2/AM (5 𝜇M; Invitrogen)
in HBSS (145mM NaCl, 5mM KCl, 1mM MgSO
4
, 1 mM
CaCl
2
, and 10mM HEPES) supplemented with 0.18% (w/v)
D-glucose and 0.2% (w/v) BSA for 30min at 37∘C in the
dark. For measurement of intracellular calcium mobilisation
in the absence of extracellular calcium, calcium-free HBSS
supplemented with 100𝜇MEGTA (ethylene glycol tetraacetic
acid) to chelate any remaining free calcium, was used. Cells
(106) were added to a stirred glass cuvette in a Hitachi F-
700 fluorescence spectrophotometer at 37∘C and stimulated
as indicated at 𝑡 = 50 s and measurements acquired for
a total of 180 s. Calcium levels were detected every 500ms
using excitation-emission ratios of 340/380 nm. Following
each experiment 𝑅max and 𝑅min values were determined by
the addition of 1% Triton-X100 and subsequent addition of
20mM EGTA pH 7.4, respectively.
2.8. Cytokine and Prostaglandin D
2
(PGD2) Release. ELISAs
for IL-6, IL-13, MCP-1, and TNF𝛼 (limits of detection
4 pg/mL, 4 pg/mL, 15 pg/mL, and 8 pg/mL resp.; eBioscience)
and PGD2 (Cayman Chemicals) were performed on tripli-
cate samples according to the suppliers’ recommendations
and developed using TMB substrate and absorbances were
determined using a TECAN Sunrise Microplate Reader.
2.9. Mast Cell Degranulation. The level of degranulation was
determined using a modified colorimetric assay to assess
the release of 𝛽-hexosaminidase. Mast cells (0.2 × 106) were
suspended in 200𝜇L Tyrode’s buffer supplemented with 1%
FCS and stimuli were added for 30min at 37∘C. Reactions
were terminated by centrifugation (400 g) and 50𝜇L aliquots
of supernatants assayed for release of 𝛽-hexosaminidase and
normalised to total cellular 𝛽-hexosaminidase following cell
lysis by the addition of 1% Triton-X 100 and by incubation
with 1mM p-nitrophenyl-N-acetyl-𝛽-d-glucosamine (NAG)
in 200𝜇L 0.05Mcitrate buffer, pH4.5. After incubation in the
dark at 37∘C for 1 h the reaction was quenched by the removal
of 62.5 𝜇L of the reaction mix into a clean well and the
addition of 125𝜇L/well 0.1M sodium bicarbonate buffer and
optical density determined by a TECAN Sunrise Microplate
Reader at 405 nm.
2.10. Western Blotting. Mast cells (2 × 106/mL) were stimu-
lated as indicated and reactions terminated by the addition
of ice-cold PBS and centrifugation at 400 g at 4∘C for
5min. Lysis was performed by the addition of 50 𝜇L ice-
cold, modified RIPA lysis buffer (50mM Tris buffer, pH
7.4 containing 150mM sodium chloride, 2% (v/v) NP40,
0.25% (w/v) sodium deoxycholate, 1mM EGTA, 10mM
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sodium orthovanadate, 0.5mM phenylmethylsulfonylfluo-
ride, chymostatin (10𝜇g/mL), leupeptin (10 𝜇g/mL), antipain
(10 𝜇g/mL), and pepstatin A (10 𝜇g/mL)). After vortexing,
the cells were incubated on ice for 30min before microcen-
trifugation of lysates at 12000 rpm for 15min. The resulting
supernatants (cell lysates) were stored at −20∘C.
Equal protein loadings of cell lysates (30–40𝜇g pro-
tein perlane), determined by BCA protein assay (bicin-
choninic acid assay; Thermo Pierce), were resolved using
the XCell SureLock Mini-Cell kit with NuPAGE Novex
high-performance precast Bis-Tris gels and NuPAGE buffers
and reagents (Invitrogen). Proteins were then transferred to
nitrocellulose (Amersham) or PVDFmembranes and protein
loading was validated by Ponceau Red staining. Membranes
were washed in Tris-buffered saline (TBS) (0.5M NaCl and
20mM Tris pH 7.5) with 0.1% (v/v) Tween-20 (TBS/Tween)
and blocked for 1 h in TBS/Tween with 5% nonfat milk
(Marvel). Membranes were then incubated overnight at
4∘C with the appropriate primary detection antibody. All
antibodies were diluted in TBS/Tween with either 5% nonfat
milk or 5%BSA. Following incubationwith primary antibody
the membranes were washed with TBS/Tween and incubated
in the appropriate horseradish peroxidase (HRP)-conjugated
secondary antibody for 2 h at room temperature before
visualisation using the ECL detection system and Kodak
X-Ray film. Densitometry was performed using Image J
software.
2.11. Statistical Analysis. All statistical analysis was per-
formed using GraphPad Prism 5.0 (GraphPad Software Inc).
Statistical analysis was by unpaired 𝑡-test or one-wayANOVA
with Tukey’s post-test and 𝑃 is significant at ∗𝑃 < 0.05,
∗∗
𝑃 < 0.01, ∗∗∗𝑃 < 0.001, and ∗∗∗∗𝑃 < 0.0001.
3. Results and Discussion
3.1. Phenotyping of PDMC, Mucosal-Type BMMC, and CTMC
Mast Cell Subsets. Following expansion of PDMC and
derivation ofmucosal-type BMMCandCTMC for 4–6weeks
in vitro, these mast cell populations were phenotyped for
mast cell lineage markers (CD117, Fc𝜀RI, and ST2) and also
for TLR4 (toll-like receptor-4) and proteoglycan (heparin)
expression (Figure 1). This analysis revealed all three mouse
subsets to be of similar size, although the CTMC appeared
rather less granular (Figure 1(a)), with each subset com-
prising a homogeneous population of CD117+Fc𝜀RI+ mast
cells (Figure 1(b)). Moreover, all 3 populations expressed
TLR4 (Figure 1(c)) and ST2 (Figure 1(d)), with BMMC typ-
ically expressing the highest levels of TLR4 and CTMC
showing most ST2 expression. Similarly, PDMC, mucosal-
type BMMC, and CTMC all contained heparin-containing
granules as indicated by toluidine blue staining (Figure 1(e)),
although there was some heterogeneity in the CTMC, and to
a lesser extent, the mucosal-type BMMC populations, per-
haps reflecting their differences in granularity (Figure 1(a)).
Mucosal-type mast cells from mice have generally been
considered to express little or no heparin, but in agreement
with our results, it has been reported that heparin expression
can be upregulated in response to SCF in these cells [14]:
this functional plasticity is consistent with the ability of
mouse BMMC to repopulate both serosal and mucosal
compartments of mast cells in vivo [14].
3.2. Differential Functional Responses of Mast Cell Subsets.
It has previously been reported that serosal- and mucosal-
type mast cells exhibit differential functional responses with
PDMC displaying strong degranulation responses whilst
BMMC preferentially produce chemokines and cytokines,
and that these responses can be further “fine-tuned” selec-
tively in response to inflammatory stimuli and microen-
vironment [14]. We therefore characterised the differ-
ential responses of PDMC, mucosal-type BMMC, and
CTMC in response to Ag-mediated crosslinking of Fc𝜀RI,
LPS/TLR4 signalling and also the pharmacological stimulus
PMA plus ionomycin (P/I) in terms of degranulation (𝛽-
hexosaminidase), eicosanoid (PGD2), chemokine (MCP-
1), and cytokine (IL-6, IL-13 and TNF𝛼) release (Table 1).
These data confirmed that PDMC were the subtype that
degranulated most strongly in response to Fc𝜀RI and PMA
plus ionomycin and demonstrated that all of these subtypes
generated in vitro exhibited little or no degranulation in
response to LPS. All of the mast cell populations consti-
tutively secreted high levels of PGD2 (lowest in PDMC);
however, whilst PDMC did not produce any more PGD2 in
response to Fc𝜀RI crosslinking, both mucosal-type BMMC
and CTMC responded further to this stimulus and also to
LPS. Further differential responses were observed in terms
of chemokine release as whilst LPS stimulated release of
MCP-1 in all subtypes, Fc𝜀RI crosslinking induced little or
no release of MCP-1 over the basal levels in PDMC, yet
strongly stimulated release of this chemokine from mucosal-
type BMMC and CTMC. Only PMA plus ionomycin were
able to induce substantial secretion of IL-6 and IL-13 by
PDMC, and none of the stimuli were routinely able to trigger
TNF𝛼 release by these cells. Similarly, whilst Fc𝜀RI- and
LPS/TLR4-signalling induced little or no IL-13 or TNF𝛼
production by CTMC, LPS, but not Fc𝜀RI crosslinking,
triggered strong secretion of IL-6. By contrast, Fc𝜀RI and
LPS/TLR4 signalling both induced the production of all
three cytokines (IL-6, IL-13 and TNF𝛼) by mucosal-type
BMMC. It has been reported that BMMC and freshly isolated
PDMC derived from C57BL/6 mice exhibited higher levels
of degranulation (𝛽-hexosaminidase) and generated lower
levels of cytokine and prostaglandin production than those
derived from BALB/c mice [38] but we did not find this to be
a significantly reproducible trend in this study (data are not
shown).
3.3. ES-62 Inhibits Functional Responses in Both Serosal and
MucosalMast Cell Subtypes. Given the differential functional
responses of the mast cell subtypes, we next investigated
whether the filarial nematode product showed selectivity in
its desensitisation of mast cell responses, both in terms of the
mast cell subtype targeted and alsowith respect to their differ-
ential responses to the individual proinflammatory stimuli.
These studies showed that exposure to ES-62 significantly
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Figure 1: Phenotyping of mast cell subsets. Exemplar plots of mast cell phenotyping by flow cytometric analysis are shown in (a)–(d). FSC
and SSC parameters of PDMC, mucosal-type BMMC, and CTMC cultured in vitro for 28 days (a) and gating (relative to isotype controls;
not shown) of the consequent CD117+Fc𝜀R1+cell population (>98%; (b)) prior to the analysis of their TLR4+expression (c) are shown. In
parallel experiments, ST2 expression of CD117+Fc𝜀R1+cells in the various populations was determined (d). Gray shaded plots (c-d) are isotype
controls. In (e), exemplar images of toluidine blue staining of the mast cell populations (x10) are shown.The data are representative of at least
2 independent experiments.
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Figure 2: Degranulation by mast cell subsets. Mucosal-type BMMC, CTMC and PDMC were sensitised with murine anti-DNP IgE
(0.5 𝜇g/mL) in the presence and absence of ES-62 (2𝜇g/mL) overnight. Cells were then stimulated with DNP (0.5 𝜇g/mL) to induce Fc𝜀RI
cross-linking (XL; (a)) or PMAplus ionomycin (both 1 𝜇M; (b)) for 30min at 37∘C.Degranulationwas determined as the% 𝛽-hexosaminidase
release relative to the total enzyme activity of the cells and the data presented are from single experiments representative of at least 2
independent experiments. PDMC were sensitised with murine anti-DNP IgE (0.5𝜇g/mL) in the presence and absence of ES-62 (2𝜇g/mL)
overnight and analysed for expression of Fc𝜀RI (c), CD117 (d), and ST2 (e). Grey shaded plots (c–e) are relevant isotype controls.
inhibited the degranulation of PDMC and the mucosal-type
BMMC, but not CTMC, in response to Fc𝜀RI signalling
(Figure 2(a)). Whilst the responses to LPS were typically
too low (Table 1) to show significant effects of ES-62 (data
not shown), degranulation in response to PMA plus iono-
mycin was also significantly inhibited in PDMC (Figure 2(b))
and likewise observed in CTMC (2/2 experiments) and the
mucosal-type BMMC (3/5 experiments).
Although PDMC produced little or no chemokines/
cytokines in response to either Fc𝜀RI crosslinking or LPS-
stimulation (Table 1), generally, the very low levels of MCP-1,
IL-6, and IL-13 observed were inhibited by ES-62 (data not
shown). With respect to mucosal-type BMMC and CTMC,
whilst ES-62 was only able to significantly inhibitMCP-1 pro-
duction by Fc𝜀RI-stimulated mucosal-type BMMC (Figures
3(a) and 3(b)), it inhibited LPS-stimulated IL-6 production
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Figure 3: Chemokine and cytokine release by mast cell subsets. Mucosal-type BMMC (a), (c) & (e) and CTMC (b), (d) & (f) were sensitised
with murine anti-DNP IgE (0.5 𝜇g/mL) in the presence and absence of ES-62 (2𝜇g/mL) overnight. Cells were then stimulated with DNP
(0.5 𝜇g/mL) to induce Fc𝜀RI cross-linking (XL) or LPS (0.5𝜇g/mL) for 24 h at 37∘C and MCP-1 (a) & (b), IL-6 (c) & (d), and IL-13 (e) & (f)
release measured by ELISA. The data presented are single experiments representative of at least 2 independent experiments apart from the
IL-13 release from CTMC, which could only be detected in a single experiment.
by both subtypes as well as that seen in mucosal-type BMMC
in response to crosslinking of Fc𝜀RI (Figures 3(c) and 3(d)).
By contrast, the IL-13 response to Fc𝜀RI crosslinking was
suppressed by ES-62 in both subtypes (Figures 3(e) and
3(f)) whilst the Fc𝜀RI-mediated TNF𝛼 response only seen in
mucosal-type BMMC was also inhibited by ES-62 (data not
shown).
Collectively, therefore, we have shown that ES-62 can tar-
get both serosal- and connective-tissue phenotypes to render
these cells hyporesponsive to proinflammatory stimuli. That
ES-62 canmodulate the responses of bothmature and imma-
ture cells is consistent with our previous studies showing
that the parasite product can target immature bone marrow
progenitors of macrophages and dendritic cells to generate
a more anti-inflammatory environment in vivo [37, 39]. The
finding that ES-62 did not modulate expression of Fc𝜀RI,
CD117, or ST2 on resting or sensitized mast cells (Figures
2(c)–2(e) and data not shown), however, suggested that it
was not affecting their phenotypic status but rather targeting
their functional plasticity. The observed differential targeting
of particular responses may indicate selective actions in par-
ticular microenvironments and consequently, recruitment of
other innate cells such as neutrophils to the site of inflam-
mation as well as mast cell promotion of the polarisation
of particular immune responses [4, 14], dependent on the
site and type of inflammation (e.g., protective inflammation
to fight infection versus aberrant autoimmune or allergic
hyperinflammation).
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Figure 4: Calcium mobilisation in mast cell subsets. Fura-2/AM-loaded resting, nonsensitised (a) & (b) or anti-DNP IgE (0.5 𝜇g/mL)-
sensitised (a)–(h) mucosal-type BMMC (e) & (f), CTMC (g) & (h) and PDMC (a)–(d) were stimulated at 50 s with DNP (0.5 𝜇g/mL) to
induce cross-linking (XL) of Fc𝜀R1 (a), (c), (e) & (g) or 0.5𝜇g/mL LPS (b), (d), (f) & (h), and intracellular calcium mobilisation and influx
recorded in real time using excitation-emission ratios of 340/380 nm (a)–(h). For analysis of intracellular mobilisation alone, the cells were
stimulated in calcium freeHBSS supplementedwith 100 𝜇MEGTA to remove all extracellular calcium (EGTA). Calcium levels were calculated
from 𝑅max and 𝑅min values and the data are presented as the mean calcium values of triplicate samples (base line calcium values subtracted)
from a single experiment representative of at least 3 independent experiments.
3.4. ES-62 Targets Calcium and PKC Signalling in Mast Cells.
To address how ES-62 may be differentially targeting the
functional responses of PDMC, the mucosal-type BMMC,
and CTMC, we investigated the effects of the parasite
product on calcium mobilisation and expression of PKC𝛼,
as we had previously shown modulation of these two key
signals in degranulation and cytokine signalling [40–42] to
be crucial to the desensitisation of Fc𝜀RI-mediated human
mast cell responses [35, 36]. Moreover, ES-62 exerts its
effects via subversion of TLR4 signalling whilst the canonical
TLR4 ligand LPS typically acts to enhance Fc𝜀RI functional
responses [43, 44], the latter accounting at least in part for
the widely established finding that LPS exacerbates airway
hyperresponsiveness [43]. LPS has been reported to do this
by increasing Fc𝜀RI-driven calcium mobilisation by upreg-
ulating the Orai1 and Stim1 subunits of the store-operated
calcium (SOC) channel and hence stimulating calcium influx
[43]. In addition, PKC signalling, including that of PKC𝛼,
has been shown to be important to LPS/TLR4 responses in
a variety of innate cells [45].
As a first step, we investigated whether Fc𝜀RI- and
LPS/TLR-signalling induced calcium mobilisation in each of
PDMC, mucosal-type BMMC and CTMC (Figure 4). Inter-
estingly we found that not only as expected, IgE-sensitisation
of mast cells was essential for Fc𝜀RI-mediated calcium
mobilisation, but also that it enhanced that seen in response
to LPS (PDMC; Figures 4(a) and 4(b)). Moreover, it was clear
that whilst the Fc𝜀RI signal reflected a mix of mobilisation
of intracellular calcium and calcium influx, as indicated by
the observed transient spike in the absence of extracellular
calcium (EGTA), the calcium response to LPS in all mast
cell subtypes predominantly reflected calcium influx (Figures
4(c)–4(h)). Consistent with LPS inducing calcium influx, we
also found as reported previously [43] that LPS enhanced
Fc𝜀RI-mediated calcium mobilisation (data not shown). By
contrast, although preexposure to ES-62 did notmodulate the
baseline calcium levels, the parasite product suppressed the
subsequent calcium mobilisation in response to both Fc𝜀RI-
crosslinking and LPS/TLR4 signalling in PDMC (Figures 5(a)
and 5(b)).
In addition, ES-62 was found to downregulate PKC𝛼
expression in PDMC, mucosal-type BMMC and CTMC
(Figures 5(c) and 5(d)), suggesting, that as with human mast
cells [35], ES-62 was targeting this signal in PDMC, mucosal-
type BMMC and CTMC to suppress degranulation and
cytokine responses. PKC𝛼 has been shown to be degraded via
both proteosomal and caveolae/lipid raft, lysosomal routes
[46, 47] and our preliminary studies in human mast cells
showed that the inhibitor of caveolae/lipid raft trafficking,
nystatin could protect against such downregulation following
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Figure 5: ES-62 modulates signalling in mast cell subsets. PDMC were sensitised with murine anti-DNP IgE (0.5𝜇g/mL) in the presence
or absence of ES-62 (2𝜇g/mL) overnight. Following loading with Fura-2/AM such PDMC were stimulated at 50 s with DNP (0.5 𝜇g/mL) to
induce cross-linking (XL) of Fc𝜀R1 (a) or 0.5𝜇g/mL LPS (b) and intracellular calcium mobilisation and influx recorded in real time using
excitation-emission ratios of 340/380 nm (a) & (b). Calcium levels were calculated from 𝑅max and 𝑅min values and data are presented as
the mean calcium values of triplicate samples from a single experiment representative of at least 3 independent experiments. PDMC and
mucosal-type BMMC (c) & (e) were cultured with ES-62 (2𝜇g/mL) for the indicated times and expression of PKC𝛼 ((c), Cell Signalling
Technology), MyD88 ((e), Abcam) and PKC𝛿 ((e), Cell Signalling Technology) analysed byWestern Blotting. In (d), following preincubation
for 1 h with inhibitors of proteosomal degradation (10𝜇M Lactacystin, ENZO Life Sciences; LAC), caveolae/lipid raft trafficking (50𝜇g/mL
Nystatin; NYS) and lysosomal degradation (E64d + pepstatin A both 10 𝜇g/mL, ENZO Life Sciences), sensitised CTMC were cultured with
ES-62 (2𝜇g/mL) for the indicated times and expression of PKC𝛼 analysed by Western Blotting. Actin was used as a loading control and
ES-62-mediated downregulation of PKC𝛼 expression was observed in PDMC, Mucosal-type BMMC, and CTMC in at least 2 independent
experiments.
exposure to ES-62 for 24 h [35]. Furthermore, our earlier
studies [48] had shown that ES-62-mediated downregulation
of PKC𝛼 expression inB cells could be prevented by treatment
with the cysteine protease inhibitor leupeptin; findings also
consistent with a lysosomal mechanism [49, 50] of degrada-
tion of this key signalling element. We have therefore further
investigated the (differential) mechanisms involved in ES-
62-driven degradation of PKC𝛼 in mast cell subtypes. Our
data in CTMC are consistent with that of our previous study
on human mast cells [35] as they showed that nystatin but
not lactacystin protected against PKC𝛼 degradation and we
have further confirmed the role of an endosomal route by
showing that protection is also afforded by the combination of
the lysosomal inhibitors, E64d plus pepstatin A (Figure 5(d)).
However, our comprehensive analysis of mechanism in
PDMC and the mucosal-type BMMC has revealed a more
complicated scenario in which both nystatin and lactacystin
can offer some protection at differential time points (data
not shown). Interestingly, these findings are consistent with
reports that both mechanisms can coexist in cells not only
in a temporal and spatially distinct manner but can also be
triggered to regulate PKC𝛼 expression in response to a single
agonist [46]. Hence, the differential recruitment of one or
more of these degradative pathways may provide a rationale
for fine tuning the level of PKC𝛼 desensitisation required
to downregulate hyperinflammatory responses; an attractive
proposal gave that CTMC exhibit the least degranulation
potential and are not as effective at producing cytokines as
the mucosal-type BMMC. Overall, as we have also found that
the inhibitors alone canmodulate PKC𝛼 expression in PDMC
andmucosal-type BMMC, these findings collectively indicate
that regulation of this key signalling element in mast cells is
tightly controlled by a complex anddynamic system involving
both proteosomal and lysosomal routes of degradation.
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Figure 6: Model of differential desensitisation of mast cell subsets by ES-62. Mucosal-type BMMC, CTMC, and PDMC exhibit differential
functional responses to antigen (Ag)-mediated cross-linking of Fc𝜀RI and stimulation with LPS as summarised. The signalling mechanisms
underlying the coupling to these differential responses and their desensitisation by ES-62 have not been fully delineated but our working
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by ES-62. Although these cells express TLR4/MyD88, they are uncoupled from downstream functional LPS signalling by an as yet unknown
mechanism. By contrast, mucosal-type BMMC exhibit both degranulation (via Ag/Fc𝜀RI) and cytokine (via Fc𝜀RI and LPS/TLR4) responses,
requiring recruitment of additional signals such as PKC𝛿 and MyD88 signalling which are both also targeted by ES-62.
Finally, whilst we have shown that ES-62 can suppress
the cytokine responses of both PDMC and the mucosal-
type BMMC, it is clear that the levels of cytokines produced
by PDMC in response to Fc𝜀RI- and LPS/TLR4 signalling
are very low compared to those secreted by mucosal-type
BMMC. We have therefore addressed identifying which
signals may be contributing to such higher levels of cytokine
production by also determining the effects of ES-62 on
PKC𝛿 expression as this signalling element has not only been
shown to be important for functional responses to Fc𝜀RI- and
LPS/TLR4 signalling [40, 45, 51–53] but also to be a target for
downregulation by the parasite product in human mast cells
and B cells [35, 48]. In addition, we have also examined the
effect of ES-62 onMyD88, a pivotal signal transducer of TLR4
[45, 51, 54] as we have shown it to be a target of ES-62 in coun-
teringTh17 pathology [37] and only the MyD88-, and not the
TRIF-dependent pathway of TLR4 signalling, appears to be
active in BMMC [55]. Consistent with the hypothesis that
additional signals such as MyD88 and PKC𝛿 are required for
the augmented cytokine responses observed in BMMC rela-
tive to PDMC, these studies show that whilst MyD88 expres-
sion in PDMC is unchanged by exposure to ES-62, culture
with the parasite product results in downregulation of both
MyD88 and PKC𝛿 in mucosal-type BMMC (Figure 5(e)).
4. Conclusions
PDMC, mucosal-type BMMC, and CTMC mast cell popu-
lations display differential functional responses with mature
serosalmast cells predominantly acting like cells that perform
a specialised degranulation function. By contrast, BMMC,
which have been reported to possess an immature mucosal-
like phenotype that can further differentiate into mucosal
or serosal mast cells display reduced degranulation and
increased cytokine responses. Consistent with the idea that
BMMC are plastic and can differentiate into either mucosal
or serosal mast cells, CTMC display a comparable degran-
ulation potential to that of mucosal-type BMMC and a
cytokine profile intermediate of mucosal-type BMMC and
mature serosal/connective tissue PDMC. All three mast cell
populations can be rendered hyporesponsive by ES-62 but
the selective nature of these effects suggests that ES-62 may
be targeting functions of the individual subtypes that are
12 Journal of Parasitology Research
specific to the particular inflammatory microenvironment
and phenotype.
The mechanisms underlying such desensitisation have
not been fully delineated but our workingmodel (Figure 6) is
that reduced degranulation and low level cytokine secretion
reflect desensitisation of Fc𝜀RI- and LPS/TLR4-mediated
calciummobilisation andPKC𝛼 signallingwhilst suppression
of the high levels of cytokine production by mucosal-type
BMMC in response to these signals requires downregulation
of additional signals such as MyD88 and PKC𝛿. Such a rheo-
stat effect allowing differential signal strength-dependent
desensitisation of receptor signalling would allow ES-62
to provide an appropriate level of hyporesponsiveness that
would prevent development of aberrant autoimmune and
allergic inflammatory disorders whilst allowing appropri-
ate levels of inflammation to generate protective immune
responses to pathogenic infection.
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